Search

Displaying results 3781 - 3790 of 8469 in total
  1. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib has a monoisotopic molecular weight of 525.2 Da. … The usage of the INN stem '-rasib' in the name indicates that Opnurasib is a Ras protein inhibitor.

  2. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    Ferrous bisglycinate is a chelate that is used as a source of dietary iron. … Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional [A27250].

  3. Drug

    Clofutriben

    go.drugbank.com/drugs/DB21636
    Investigational

    Clofutriben has a monoisotopic molecular weight of 424.09 Da. … Clofutriben is under investigation in clinical trial NCT05307328 (SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome).

  4. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  5. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.

  6. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and [agalsidase beta], pegunigalsidase alfa uses a plant cell-based protein expression system, leading … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  7. Drug

    Aztreonam

    go.drugbank.com/drugs/DB00355
    ApprovedInvestigational

    A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinf...

  8. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The development of PW2101 has since been discontinued. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  9. Drug

    Dengue virus serotype 4

    go.drugbank.com/drugs/DB22667
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]

  10. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.